GenePoint Bio Completes Nearly RMB 200 Million Series D Financing, Start Capital Serves as Exclusive Financial Advisor

VCBeat recently learned that,Provider of Intelligent Ultra-Low Temperature Biological Cryopreservation System Solutions——genepoint, recently completedSeries D Financing. This financing round was led byGuofang Capital Leads Investment，Huajin Investment, Guosheng Capital, Guangda Huitong, and Guolian Tongbao participated in co-investment，Existing shareholders Deyi Capital and LYFE Capital continue to make substantial additional investments, Financing AmountTotal approximatelyRMB 200 million。Qidian Capital served as the exclusive financial advisor for this round of financing. According to reports, the funds raised in this financing round will be used for the construction of the company's production bases across its entire industry chain and for the deployment of its global strategy.

genepoint was founded in 2015, after more than seven years of rapid development, the company currentlyA full-process layout has been completed, spanning R&D systems, supply chain development, mass production, and global commercialization.Prior to this round of financing, the company had already secured hundreds of millions of yuan in funding from well-known institutions and industrial capital firms, including Aurora Venture Capital, Zhouling Capital, Deyi Capital, MGI Tech, Houxin Health Investment, Chengtan Network, and Legend Star.

It is reported that, as a startup, genepoint has stood out in the fiercely competitive life sciences tools sector. In addition to its solid founding team, deep industry insights, and the booming market for life sciences tools, two other factors have also played a crucial role.

The biological resource preservation industry serves as the cornerstone of human life and health development, acting as the most fundamental platform for precision medicine and cutting-edge biological research. It is widely applied in fields such as clinical sample collection from patients for medical research, epidemiological and public health studies, cohort studies for clinical and health research, sample storage for biopharmaceutical R&D, cell therapy, genetic testing, assisted reproduction, conservation of animal and plant germplasm resources, and forensic evidence identification. Many of these precious samples,Requires long-term storage at ultra-low temperature (-80°C) or cryogenic temperature (-196°C).. Therefore, how to achieve long-term stable operation of mechanical components in this extreme environment,Genepoint has shifted its problem-solving approach to outer space.。

Since Earth lacks extreme working environments capable of achieving cryogenic temperatures, the conductive structures of motors sourced from traditional industrial supply chains cannot function under such cryogenic conditions.Yet such extreme environments are commonplace in outer space beyond Earth.

Genepoint has pioneered a technical approach that fully integrates cryogenic-resistant mechanical components, sourced from the aerospace and defense supply chain, within the cryogenic chamber, thereby enabling "isothermal operation" of the storage and working zones.Meets the requirements for temperature-fluctuation-free access throughout the entire lifecycle of stored samples, thereby preserving sample integrity, avoiding interference with experimental results, and achieving high-level biosafety protection. 

From the perspectives of global commercialization layout and technological demand, the Company has established its strategic and commercialization center in Shanghai, laying a solid foundation for rapid market expansion and penetration. Meanwhile, the Company has also built a full-chain engineering center in Chengdu, covering R&D, pilot trials, supply chain management, production management, process quality control, and after-sales service.Achieving a Breakthrough in Deep Cryogenic Automation Technology from “Customization” to “Mass Production”. AlsoMarking that China has achieved full independent intellectual property rights in the technological development and manufacturing of ultra-low temperature cryopreservation equipment., no longer constrained by overseas suppliers, and has established a solid foundation for capturing overseas markets with the new generation of "Intelligent Manufacturing in China."

At the inception of the company, the founding team of genepoint recognized that the life science tools sector suffered from a significant lack of brand awareness and, even more critically, a shortage of pioneers daring to build high-end brands. Leveraging genepoint’s unique technological pathways and capitalizing on the historical opportunity presented by the rise of China as a global power,Since its product launch in 2017, genepoint has clearly established a fundamental strategy of building a high-end global brand.. To align with this strategy, the company’s brand and product teams have spared no effort, breaking away from the conventions of the traditional medical device industry in terms of brand positioning, industrial design, and marketing communication. By innovating a series of market strategies, they have established a highly recognizable brand image in China within just a few years.

Meanwhile, the company’s commercialization team is also composed of professionals from leading international brands in the life sciences tools sector. This team has effectively implemented a comprehensive and multi-dimensional strategy encompassing brand, promotion, and service initiatives, rapidly elevating Genepoint’s brand visibility to an industry-recognized status within a short period.

The direct result of the brand strategy isGenepoint has never engaged in any "price war" since its market entry., and even in many casesGenepoint's product pricing is also higher than that of foreign competitors., which is a source of great pride for the entire team and investors. It is precisely based on these successive “victories” in China that Genepoint will have greater confidence to make significant strides forwardExpanding into Overseas Markets。

Reviewing the industry’s development over the past five years, continuous breakthroughs in biotechnology have propelled the global life sciences tools sector into a phase of rapid growth. We have every reason to believe that, given fertile market conditions, this sector will—much like many other fields now dominated by “Made in China” products—see the emergence of a cohort of companies rooted in Chinese intelligent manufacturing within the foreseeable future. This is driven by China’s world-class supply chain, a sustained dividend of engineering talent, a sophisticated investor base, and successive waves of entrepreneurs with strong entrepreneurial spirit.

Guided by its mission to “make life exploration better,” genepoint is steadily advancing toward its goal of becoming a leading global life science instrumentation company.

Wei Yaguang, Partner at Guofang CapitalGuofang Capital remains bullish on the development opportunities for upstream tools driven by the iterative advancements in life science technologies. Leveraging its profound insights into application scenarios, robust technological accumulation, and clear product roadmap, Genepoint has achieved domestic superiority through “Intelligent Manufacturing in China.” Guofang Capital is honored to partner with Genepoint to jointly facilitate the intelligent upgrade and transformation of the life sciences industry.

Dr. Xinle Niu, Managing Director of Huajin InvestmentIt is stated that in the field of upstream equipment and consumables for life sciences, genepoint has elevated import substitution to a stage of global innovation. With a profound understanding of life science applications, genepoint has driven advancements in the field of cryogenic storage through novel design concepts and innovative equipment, software, and consumables. Huajin Investment is pleased to participate in this process of industrial progress.

Dr. Xiao Xinye, Deyi CapitalStated: This round marks Deyi Capital’s third increased investment in Genepoint. Over the years as a shareholder, we have witnessed the company’s growing maturity in team building, product development, and supply chain layout. We look forward to and believe that the company’s existing products will continue to achieve steady growth, while its newly launched products will rapidly scale up in volume.

LYFE Capital (Zhouling Capital)Stated: Over the past year, the genepoint team achieved outstanding results through strong execution, delivering rapid counter-trend growth in a highly challenging environment. The company developed multiple new product lines with significant growth potential, solidifying its position as the domestic leader in intelligent automated ultra-low temperature solutions. Continued recognition from leading customers has further enhanced its brand influence. LYFE Capital will continue to support the company’s overseas market expansion through resources within its global ecosystem, aiming to build a globally recognized platform enterprise.

Ma Jialie, Head of the Greater Health Industry and Managing Director at Guolian TongbaoStatement: Guolian Tongbao remains bullish on independent controllability and domestic technological innovation in the life sciences sector, as well as the role of automation and informatization in driving the upgrading of the medical industry. As a leading provider of intelligent automated ultra-low temperature biological storage solutions, genepoint has achieved true source-level innovation and commercial viability, gaining recognition from top-tier users in a short period, rapidly establishing its brand influence within the industry, and continuing to lead the direction of industry automation. Guolian Tongbao is honored to partner with genepoint, supporting the company in becoming a global leader in intelligent ultra-low temperature biological storage systems.

Wang Shiyi, Investment Director at Guangda HuitongGenepoint boasts a top-tier team in the industry, having developed several highly promising product lines within just a few years. During the pandemic, the company achieved counter-trend growth. Meanwhile, we are very optimistic about the field of ultra-low temperature automation, which is a critical link in life sciences. Genepoint’s products can help avoid potential supply chain bottlenecks in the future. Guangda Huitong is honored to accompany Genepoint in its development journey. In the future, we hope to support the company by leveraging Guangda Huitong’s ecosystem resources in semiconductors and hard technology, helping Genepoint become a global leader in ultra-low temperature automation.

Ms. Ye Lan, Founding Partner of Qidian CapitalStatement: We extend our sincere gratitude to the Genepoint team and existing shareholders for their close support and cooperation throughout the financing process. Qidian Capital is honored to have served as the exclusive financial advisor for this round of financing. We deeply admire the founding team’s innovative capabilities in independent R&D, their profound industry insights, and their strong ability to integrate resources. We remain bullish on the company’s future development and believe that, with capital support, Genepoint will further solidify its position as a promoter and leader in the international intelligent ultra-low temperature biopreservation systems sector.

Guofang Capital is a venture capital firm dedicated to realizing technological value, with a focus on hard technology. Upholding the spirit of “dancing with technology and advancing with the times,” Guofang Capital firmly believes in leveraging capital chains to drive innovation chains and connecting innovation chains with industrial chains. By strategically investing in specialized VC funds, industry-chain funds, and outstanding technology enterprises, Guofang focuses on three key frontier sectors: biomedicine, artificial intelligence, and the Internet of Things (IoT). It aims to guide broader social capital, build an ecosystem that integrates resources from governments, industrial parks, finance, and industry, support the growth of innovative enterprises, and continuously enhance and optimize the industrial chain ecosystem.

Huajin Investment is an investment platform under Huafa Group, a state-owned enterprise in Zhuhai and one of China’s Top 500 Enterprises. With total assets exceeding RMB 600 billion, Huafa Group is the largest comprehensive corporate group in Zhuhai and has been listed among the “China Top 500 Enterprises” for seven consecutive years. In the field of industrial investment, Huafa Group focuses on four key sectors, including new energy vehicles, semiconductors, and biopharmaceuticals, achieving strong performance. Its investment entities include Huajin Capital, Infinity Group, Zhuhai Science and Technology Innovation Investment, and other platforms. Notably, Huajin Capital has been repeatedly ranked among Zero2IPO’s “Top 50 Private Equity Firms in China” and was recognized as one of the “Top 20 Best New Energy Investment Institutions” in 2022. To date, through investment platforms such as Huajin Investment, Huafa Group has invested in more than 300 industry-leading and high-growth innovative companies. Portfolio companies include Sunwoda Electric Vehicle Battery, Gokin Solar, Aiko Solar, Qinghai Lihao Semiconductor, Innosilicon, Narui Radar, Chipone Technology, MGI Tech, and UBTECH Robotics.

Deyi Capital, established in 2016, focuses on investments in healthcare, information technology, and green industries. Its management team possesses extensive experience in investment, investment banking, and industrial operations, along with broad market resources and specialized post-investment service and management capabilities. In the healthcare sector, Deyi Capital has invested in industry-leading and innovative enterprises, including Zeltiq Pharma (688266.SH), Allist Pharmaceuticals (688578.SH), Yifang Biopharma, Boyun Biopharma, Manteia Data Technology, Feishuo Biotech, Huamai Taico, Huiyi Huiying, Jingyu Medical, Genepoint, Shangyi Shukang, and Nuofeng Pharmaceutical.

LYFE Capital is a globally leading healthcare investment platform. We firmly believe that "healthcare knows no borders," and every investment decision we make is dedicated to advancing biomedical progress and addressing unmet clinical needs worldwide. Leveraging our extensive investment management expertise and global industry resources, LYFE Capital creates value for its portfolio companies. Our integrated international investment team provides comprehensive support to cutting-edge enterprises at all stages, helping entrepreneurs fully realize their growth potential in the global market.

Guosheng Capital is a state-owned industrial investment firm rooted in the Chengdu Tianfu International Bio-town, dedicated to serving the global development of innovative life sciences. It has established a synergistic cluster of seven parent-subsidiary industry funds, with a total scale exceeding RMB 8 billion. The firm has completed investments in more than 50 outstanding enterprises in the biopharmaceutical sector, covering five major areas: modern biotech drugs, innovative chemical drugs, high-performance medical devices, professional outsourcing services, and health services. Guosheng Capital has achieved remarkable results in industry incubation, nurturing two listed companies, four unicorn enterprises, and numerous “Specialized, Refined, Differential, and Innovative” (SRDI) enterprises. The firm was honored as one of the Top 10 Best Emerging VC Investment Institutions in China by CVCRI in 2021, one of the Top 10 Most Growth-Potential Venture Capital Institutions in China by ChinaVenture in 2021, and received the 2022 Chengdu New Economy Venture Capital Outstanding Contribution Award. Adhering to the model of “government guidance + market logic + professional operation,” Guosheng Capital is committed to becoming the most influential comprehensive financial service provider in the domestic industry.

Guolian Tongbao Capital Investment Co., Ltd. (“Guolian Tongbao”) is a private equity fund management subsidiary of Guolian Securities Co., Ltd. (Stock Codes: 601456.SH; 1456.HK; “Guolian Securities”). Established in January 2010 with a registered capital of RMB 600 million, it is among the first batch of investment management institutions to obtain licenses for private equity subsidiaries of securities companies and to participate in the direct investment pilot program. Headquartered in Wuxi, Jiangsu Province, the company leverages the comprehensive financial platforms of its shareholders, including the Wuxi Municipal Government, Guolian Group, and Guolian Securities, to conduct private equity investment and asset management businesses. Adhering to medium-to-long-term value investment strategies based on systematic research into technology, industry trends, policies, and corporate fundamentals, Guolian Tongbao currently manages funds totaling nearly RMB 5 billion. The company’s team features diverse backgrounds and extensive experience in equity investment, securities markets, corporate management, and capital operations, while possessing abundant government, financial, and industry resources as well as strong coordination capabilities.

Beijing Guangda Huitong Engineering Technology Research Institute serves as the secretariat unit of the Zhongguancun Rongxin Financial Informatization Industry Alliance. Together with JianGuang Asset Management and Wisdom Road Capital, it forms the alliance’s core investment platform. The institute primarily focuses on market opportunities in strategic emerging sectors at the international forefront—such as integrated circuits, artificial intelligence, the Internet of Things (IoT), 5G communications, and general health—as well as the latest developments in the financial industry. Guangda Huitong has established deep collaborations with Tsinghua University’s Hospital Administration Institute, Huajin Investment, Taiwanese consortiums, and renowned U.S. biomedical investment firms, with a particular emphasis on innovative drugs and medical devices.

Start Capital is a boutique investment bank headquartered in Shanghai, specializing in the healthcare and life sciences sectors. Its core team members hail from top-tier medical and financial institutions both domestically and internationally, bringing forward-looking global perspectives as well as exceptional expertise in investment, entrepreneurship, operational management, and corporate governance. Leveraging a comprehensive healthcare ecosystem and extensive capital market resources, Start Capital bridges the gap between capital and enterprises. It empowers healthcare technology companies by providing a suite of value-added services, including equity financing, strategic planning, and post-investment management, accompanying each client as they embark on new beginnings.